Los Angeles Capital Management LLC Buys 22,915 Shares of Bioventus Inc. $BVS

Los Angeles Capital Management LLC increased its stake in shares of Bioventus Inc. (NYSE:BVS) by 23.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 121,835 shares of the company’s stock after buying an additional 22,915 shares during the period. Los Angeles Capital Management LLC owned 0.15% of Bioventus worth $807,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Nantahala Capital Management LLC lifted its position in Bioventus by 2.5% during the first quarter. Nantahala Capital Management LLC now owns 4,125,650 shares of the company’s stock worth $37,750,000 after acquiring an additional 98,841 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Bioventus by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,554,224 shares of the company’s stock valued at $23,371,000 after purchasing an additional 92,143 shares during the last quarter. Driehaus Capital Management LLC increased its stake in shares of Bioventus by 29.1% during the first quarter. Driehaus Capital Management LLC now owns 1,445,257 shares of the company’s stock worth $13,224,000 after purchasing an additional 325,402 shares during the period. American Century Companies Inc. lifted its holdings in Bioventus by 18.0% during the 1st quarter. American Century Companies Inc. now owns 1,044,212 shares of the company’s stock worth $9,555,000 after purchasing an additional 159,539 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in Bioventus by 21.8% during the 1st quarter. Royce & Associates LP now owns 892,216 shares of the company’s stock worth $8,164,000 after purchasing an additional 159,980 shares during the last quarter. 62.94% of the stock is owned by institutional investors.

Insider Activity at Bioventus

In related news, Director Michelle Mcmurry-Heath sold 17,701 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $7.42, for a total value of $131,341.42. Following the transaction, the director directly owned 56,997 shares in the company, valued at approximately $422,917.74. This represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 33.00% of the company’s stock.

Bioventus Stock Performance

Shares of NYSE BVS opened at $7.57 on Friday. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a market cap of $625.88 million, a price-to-earnings ratio of -12.41 and a beta of 0.80. The stock’s fifty day moving average price is $6.98 and its two-hundred day moving average price is $6.88. Bioventus Inc. has a one year low of $5.81 and a one year high of $12.61.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.